Analysis of Retracted Publications on Methotrexate.

Abstract

Background: Methotrexate (MTX) is a frequently used antifolate agent in rheumatology, oncology, and dermatology. Retractions are crucial for preserving scientific integrity by fixing the literature when errors, ethical violations, or data falsification are detected. This study seeks to comprehensively examine retracted MTX publications, detecting trends, reasons, and potential ramifications.

Methods: A descriptive cross-sectional study was performed by searching PubMed for retracted MTX publications without temporal constraints. Bibliometric data were retrieved, encompassing publication details, journal indexing, citation metrics, and Altmetric Attention Scores (AAS). Reasons for retraction were categorized.

Results: Thirty-six retracted papers were identified. The predominant cause for retraction encompassed data concerns (n = 15), fraudulent activity (n = 11), and manipulation of the peer review process (n = 10). China recorded the most retractions (n = 14), followed by the USA (n = 6) and Egypt (n = 3). The median period until retraction was 712 (91-9,893) days. Most retracted articles were published in non-rheumatology journals. Citation analysis showed a median of 5 (0-105) citations. Additionally, the median AAS was 1 (0-14).

Conclusion: Data integrity concerns, fraudulent activities, and manipulation of peer review processes constitute major obstacles in MTX-related research. The considerable number of retractions in certain countries underscores the need to promote research ethics and measures to protect scientific integrity. Enhancing peer review, implementing more intense data transparency, and promoting post-publication evaluation are essential measures to protect scientific integrity and uphold confidence in clinical recommendations.